recurrent uterine corpus cancer
Showing 1 - 8 of 8
Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in United
Recruiting
- Endometrial Undifferentiated Carcinoma
- +6 more
- Capivasertib
- +4 more
-
Birmingham, Alabama
- +741 more
Feb 2, 2023
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma
Active, not recruiting
- Recurrent Endometrial Endometrioid Adenocarcinoma
- +4 more
-
Anchorage, Alaska
- +584 more
Jan 28, 2023
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States
Active, not recruiting
- Endometrial Adenocarcinoma
- +9 more
- Bevacizumab
- +5 more
-
Phoenix, Arizona
- +232 more
Jan 12, 2023
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma Trial in
Active, not recruiting
- Endometrial Adenosquamous Carcinoma
- +9 more
- Cabozantinib S-malate
- +2 more
-
Duarte, California
- +18 more
Oct 15, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in
Completed
- Endometrial Endometrioid Adenocarcinoma
- +5 more
- Copanlisib
- Laboratory Biomarker Analysis
-
New Haven, Connecticut
- +42 more
Jan 25, 2022
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Mucinous Adenocarcinoma, Endometrial
Active, not recruiting
- Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
- +7 more
- 3-Dimensional Conformal Radiation Therapy
- +3 more
-
Auburn, California
- +440 more
Sep 28, 2021
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma Trial in United States
Completed
- Endometrial Adenocarcinoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Hartford, Connecticut
- +21 more
Oct 13, 2020